Nontuberculous mycobacterial lung disease

Current Opinion in Infectious Diseases

Volumn 23, Issue 2, 2010, Pages 185-190

  Griffith, David E ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Mycobacterium abscessus; Mycobacterium fortuitum; Myocbacterium avium complex; Nontuberculous mycobacteria

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BODY MASS; BRONCHIECTASIS; ERM GENE; FUNNEL CHEST; HUMAN; INFECTION SENSITIVITY; LUNG INFECTION; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MITRAL VALVE PROLAPSE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM FORTUITUM; REVIEW; SCOLIOSIS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BRONCHIECTASIS; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG; MACROLIDES; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PNEUMONIA, BACTERIAL;

EID: 77649269175     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328336ead6     Document Type: Review

References (22)

1. Griffith DE, AksamitT, Brown-Elliott BA, etal. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial dis eases. Am J Respir Crit Care Med 2007; 175:367-416.
2. Feazel LM, Baumgartner LK, Peterson KL, et al. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci USA 2009; 106:16393-16399.
3. Marras TK, Wallace RJ Jr, Koth LL, et al. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005; 127:664-671.
4. Falkinham JO 3rd, Iseman MD, de Haas P, van Soolingen D. Mycobacterium avium in a shower linked to pulmonary disease. J Water Health 2008; 6:209-213.
5. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066-1074.
6. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and antitumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15:1556-1561.
7. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007; 62:661-666.
8. Iseman MD, Marras TK. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 2008; 178:999-1000.
9. Cassidy PM, Hedberg K, Saulson A, et al. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49:e124-e129.
10. van Ingen J, Boeree MJ, de Lange WC, et al. Clinical relevance of Myco bacterium szulgaiin The Netherlands. Clin Infect Dis 2008; 46:1200-1205.
11. van Ingen J, Boeree MJ, Dekhuijzen PN, et al. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J 2008; 31:106-109.
12. Park S, Suh GY, Chung MP, et al. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med 2008; 102:437-442.
13. Jun HJ, Jeon K, Um SW, et al. Nontuberculous mycobacteria isolated during the treatment of pulmonary tuberculosis. Respir Med 2009; 103:1936-1940.
14. Kitada S, Kobayashi K, Ichiyama S, MAC Serodiagnosis Study Group. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med 2008; 177:793-797.
15. Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005; 55:170-177.
16. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367-1376.
17. Cattamanchi AA, Nahid P, Marras TK, et al. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 2008; 133:875-880.
18. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J 2003; 21:478.
19. Jenkins PA, Campbell IA, Banks J, et al. Clarithromycin vs. ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63:627-634; Erratum in: Thorax. 2008 Sep;63:844.
20. Andrejak C, Lescure FX, Pukenyte E, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009; 64:291-296.
21. van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14:385-389.
22. Jeon K, Kwon O, Lee N, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180:896-903.